VerityRank
Amplifon S.p.A.
CompanyItaly

Amplifon S.p.A.

Amplifon

Amplifon S.p.A. is an Italian hearing care company headquartered in Milan and founded in 1950. It sells hearing instruments and audiological services through more than 10,000 points of sale in 26 countries across EMEA, the Americas and Asia-Pacific, and employed 15,078 people at 31 December 2025. The company is listed on Borsa Italiana's Euronext Milan under ticker AMP, with a secondary quotation on XETRA under AXNA. Control sits with Ampliter S.r.l., the Holland family holding chaired by Susan Carol Holland, which held 38.69% of issued share capital and 70.09% of voting rights as of May 2026 through a loyalty voting structure. FY2025 revenue was USD 2.81 billion, net income USD 107.3 million, and total assets EUR 3.89 billion against equity of EUR 0.9985 billion. A reserved capital increase of 56 million shares to GN Store Nord A/S, approved by shareholders in October 2026, will dilute Ampliter to 32.07% of capital and 63.69% of voting rights once the EUR 2.3 billion GN Hearing acquisition closes.

Strengths: Retail density is the core asset: over 10,000 points of sale give Amplifon a fitting and aftercare network that device manufacturers cannot replicate quickly, and the multi-brand portfolio (Amplifon, Miracle-Ear, GAES, Beter Horen, Bay Audio, Attune, Dilworth) lets it address different reimbursement regimes with local names. Revenue grew from USD 2.21 billion in FY2021 to USD 2.81 billion in FY2025, a 27% increase that outpaced most hearing-aid wholesale markets. The EUR 2.3 billion GN Hearing purchase converts Amplifon from a pure retailer into a vertically integrated manufacturer and retailer, with management targeting EUR 60–80 million of run-rate EBITDA synergies. The loyalty voting structure keeps the Holland family's 70.09% voting position intact through the transaction, providing strategic continuity.

Weaknesses: Profitability is thin and deteriorating: net income fell from USD 191.0 million in FY2022 to USD 107.3 million in FY2025, a 44% decline, on revenue that rose over the same period. Equity contracted from EUR 1.1502 billion in FY2024 to EUR 0.9985 billion in FY2025, leaving leverage-sensitive room for the GN deal. The acquisition carries integration risk at scale, and the EUR 600 million senior unsecured notes proposed in November 2026 were assigned a BB+ rating, below investment grade. Operational exposure is also visible: Amplifon Americas disclosed a security incident affecting patient and member data in November 2026, and the 56-million-share issuance to GN dilutes existing holders and reduces the family's capital stake to 32.07%.

Read More
ItalyFounded 195015078Operates over 10,000 points of… / 100
Last updated: 2026-11-15 22:21 ET·By VerityRank Research Team·Methodology

Listed market data

2 Listings · weeklyHistory →
Market cap
$3.5 B
Share price
EUR 11.86
1Y change
-12.9%
Recent change
+0.3%

11-13 → 11-16

Since first close
+660.3%

from 2001-10

Revenue (TTM)
$2.8 B
BIT: AMP · Revenue FY 2025 · updated 2026-11-15 22:21 ETSource ↗

Financial history

Full market history
EUR 0.0$0EUR 3.8$1.25 BEUR 7.5$2.5 BEUR 11.3$3.75 BEUR 15.0$5.0 B2025-122026-012026-022026-032026-042026-052026-062026-072026-082026-092026-102026-11
MonthCloseMarket capChange
  • 2026-11EUR 11.86$3.5 B+6.2%
  • 2026-10EUR 11.17$3.3 B-7.7%
  • 2026-09EUR 12.10$3.6 B-0.1%
  • 2026-08EUR 12.11$3.6 B-0.3%
  • 2026-07EUR 12.15$3.6 B+28.2%
  • 2026-06EUR 9.48$2.8 B-12.1%
  • 2026-05EUR 10.78$3.2 B+14.7%
  • 2026-04EUR 9.40$2.8 B0.0%
  • 2026-03EUR 9.40$2.8 B-28.7%
  • 2026-02EUR 13.18$3.9 B-3.1%
  • 2026-01EUR 13.59$4 B-1.2%
  • 2025-12EUR 13.75$4.1 B—
Monthly closes · 2025-12 – 2026-11 · Full market history

Ownership & Control

Latest available filings
Controlling entity
Ampliter S.r.l. (Holland Family) — 38.69%
Company type
Company
Insiders
35.01%
Institutions
22.39%(170 holders)
Free float
38.47%

Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.

In the press

All coverage →4 latest headlines
Headlines aggregated from public feeds. Sentiment tags are keyword-based, not editorial judgement.

Amplifon is the largest pure-play hearing care retailer by store count, and the 2026 purchase of GN Hearing changes what kind of company it is. The research view weighs a dense but low-margin retail network against the manufacturing capability and balance-sheet strain that the EUR 2.3 billion deal brings.

Industry Position

Hearing care is a consolidated retail market sitting downstream of a concentrated manufacturing base. Sonova, Demant, WS Audiology and Starkey supply most hearing instruments globally, and Amplifon has historically bought from them while competing with Fielmann and others for the consumer. Its 10,000-plus points of sale in 26 countries make it the largest specialised retail network in the sector, and brands such as Miracle-Ear, GAES and Beter Horen give it local recognition that a single global name would not achieve. Scale in retail matters because fitting, follow-up visits and aftercare drive repurchase and referral, and because clinic density spreads fixed costs across a local market.

The GN Hearing acquisition moves Amplifon upstream into that manufacturing oligopoly. On completion it becomes both a customer and a competitor of the suppliers it has depended on, which changes bargaining dynamics across the whole portfolio. The European Commission cleared the deal in November 2026, and shareholders approved the reserved capital increase for GN in October 2026, so the strategic shift is now a question of execution rather than approval.

Competitive Advantages

The retail network is the durable advantage. Over 10,000 points of sale and 15,078 employees create a service footprint that takes years and capital to replicate, and the multi-brand structure lets Amplifon adapt to reimbursement rules country by country rather than forcing one model across 26 markets. Revenue rose from USD 2.21 billion in FY2021 to USD 2.81 billion in FY2025, showing the network can grow organically and through acquisition.

Ownership stability is a second advantage. Ampliter holds 70.09% of voting rights through the loyalty structure, so the family can commit to a multi-year integration without short-term shareholder pressure. The GN deal also brings manufacturing margin into a business that has earned thin retail returns, with EUR 60–80 million of run-rate EBITDA synergies targeted. AmplifonX and the Fit4Growth clinic optimisation programme give management levers on digital service delivery and store productivity that do not require new capital.

Strategic Expansion

The logic of the GN Hearing purchase is vertical integration: capture the device margin that currently flows to suppliers, secure supply of hearing instruments for the retail network, and use combined scale to fund research. The 56-million-share issuance to GN makes the manufacturer a shareholder, aligning its interests with the integration. The EUR 600 million senior unsecured notes proposed in November 2026 fund the cash portion, and the BB+ rating assigned to them reflects a leveraged but manageable profile.

Execution now turns on three things: retaining clinic-level service quality while absorbing a manufacturing organisation, delivering the targeted synergies, and managing the dilution that takes Ampliter from 38.69% of capital to 32.07%. The loyalty voting structure preserves control through that shift, which matters because integration decisions will span several years.

Risks & Outlook

The first risk is earnings quality. Net income fell from USD 191.0 million in FY2022 to USD 107.3 million in FY2025 even as revenue grew, and equity slipped from EUR 1.1502 billion to EUR 0.9985 billion over the same year. A leveraged acquisition layered onto a declining profit base leaves little buffer if synergies arrive late. The second risk is integration and channel conflict: Amplifon now competes with the manufacturers that still supply part of its network, and any supply disruption would hit clinics directly. The third is operational and regulatory exposure, illustrated by the November 2026 security incident at Amplifon Americas affecting patient and member data, and by the country-by-country reimbursement rules that govern pricing.

The outlook depends on whether manufacturing margin and retail density compound or cancel. If the EUR 60–80 million synergy target is met and clinic productivity holds, Amplifon emerges as a vertically integrated hearing care group with a defensible cost position. If profit continues to erode while debt service rises, the retail network becomes a fixed-cost burden. On balance the network, the family control structure and the cleared GN transaction support a favourable but execution-dependent view. VerityRank Score of 75/100.

Quick Facts

Headquarters

Milan, Italy

Founded

1950

Employees

15078

Market cap

$3.5 B

Factories

Operates over 10,000 points of sale globally as of FY2025, comprising corporate-owned direct hearing care clinics, shop-in-shops and medical corners, and franchise locations across Europe, the Americas, and Asia-Pacific, alongside global headquarters and the AmplifonX digital R&D hub in Milan, Italy.

Presence

26 countries across Europe, the Middle East and Africa (EMEA), the Americas, and Asia-Pacific (APAC)

Listing

BIT: AMP / XETRA: AXNA
Categories
Instruments & Meters

Related

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website